Chronic Kidney Disease

The mortality rate among patients with chronic kidney disease who are not on dialysis is more than twice that of people without CKD, according to the latest annual report of the United States Renal Data System.

Among adults with chronic kidney disease and type 2 diabetes, the mineralocorticoid receptor inhibitor antagonist finerenone reduced the incidence of CV events regardless of CVD status, according to new data from the FIDELIO trial.

Study findings suggest Black and Hispanic patients are at greater risk for developing kidney failure due to faster decline in kidney function following chronic kidney disease onset vs. white patients.

For patients with heart failure, empagliflozin led to reduced risk for cardiovascular mortality and heart failure hospitalizations, while slowing kidney function decline regardless of chronic kidney disease status at baseline.

Linda F. Fried, MD, MPH, FASN, co-chair of ASN Kidney Week Education Committee, discussed data presented at ASN Kidney Week showing finerenone effective in slowing the progression of chronic kidney disease in patients with diabetes.

An approach that uses artificial intelligence by including cardiac biomarkers into a machine learning algorithm more accurately predicted atrial fibrillation in patients with chronic kidney disease than use of a previously published model.

Vadadustat did not meet the primary safety endpoint of the PRO2TECT program for the treatment of anemia in patients with non-dialysis-dependent chronic kidney disease, according to data presented at ASN Kidney Week.

Jay B. Wish, MD, professor of clinical medicine at Indiana University School of Medicine and co-chair of the Nephrology News & Issues Editorial Advisory Board, talked about a subanalysis presented at ASN Kidney Week on roxadustat.

Jay B. Wish, MD, clinical medicine professor at Indiana University School of Medicine, reported that roxadustat was not linked to increased risk for neoplasm in patients with nondialysis- and dialysis-dependent chronic kidney disease.

In this video, Jay B. Wish, MD, professor of clinical medicine at Indiana University School of Medicine, discussed the insufficiency of current anemia treatment for non-dialysis-dependent patients with chronic kidney disease.